BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 98

Insulin Drug Delivery Development Drugs 98

pharmaphorum

FEBRUARY 3, 2022

Innovations in Formulation and Device Design for Enhanced Subcutaneous Delivery. As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds. reaching £915 billion by 2027.

Drug Delivery 52

Drug Delivery Drugs Engineer Scientist 52

pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59

Insulin Trials Development Drugs 59

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

pharmaphorum

JULY 27, 2021

Drug delivery specialist Aptar Group has agreed a deal to take a near two-thirds share in Voluntis, a French developer of digital therapeutics (DTx), with a view to taking full control of the company later this year. per share in the initial deal, which will give it a 64.6% stake in the company.

Drug Delivery 111

Drug Delivery Insulin Cosmetics Development 111

Roots Analysis

MARCH 21, 2022

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Marketing 52